CAMK2N1/RUNX3 Methylation is an Independent Prognostic Biomarker for Progression-free and Overall Survival of Platinum-sensitive Epithelial Ovarian Cancer Patients

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2021 Jan 23

PMID 33482905

Citations 10

Authors

Karolin Heinze

Matthias Rengsberger

Mieczyslaw Gajda

Lars Jansen

Linea Osmers

Leticia Oliveira-Ferrer

Barbara Schmalfeldt

Matthias Durst

Norman Hafner

Ingo B Runnebaum

Affiliations

Soon will be listed here.

Abstract

Background: To date, no predictive or prognostic molecular biomarkers except BRCA mutations are clinically established for epithelial ovarian cancer (EOC) despite being the deadliest gynecological malignancy. Aim of this biomarker study was the analysis of DNA methylation biomarkers for their prognostic value independent from clinical variables in a heterogeneous cohort of 203 EOC patients from two university medical centers.

Results: The marker combination CAMK2N1/RUNX3 exhibited a significant prognostic value for progression-free (PFS) and overall survival (OS) of sporadic platinum-sensitive EOC (n = 188) both in univariate Kaplan-Meier (LogRank p < 0.05) and multivariate Cox regression analysis (p < 0.05; hazard ratio HR = 1.587). KRT86 methylation showed a prognostic value only in univariate analysis because of an association with FIGO staging (Fisher's exact test p < 0.01). Thus, it may represent a marker for EOC staging. Dichotomous prognostic values were observed for KATNAL2 methylation depending on BRCA aberrations. KATNAL2 methylation exhibited a negative prognostic value for PFS in sporadic EOC patients without BRCA1 methylation (HR 1.591, p = 0.012) but positive prognostic value in sporadic EOC with BRCA1 methylation (HR 0.332, p = 0.04) or BRCA-mutated EOC (HR 0.620, n.s.).

Conclusion: The retrospective analysis of 188 sporadic platinum-sensitive EOC proved an independent prognostic value of the methylation marker combination CAMK2N1/RUNX3 for PFS and OS. If validated prospectively this combination may identify EOC patients with worse prognosis after standard therapy potentially benefiting from intensive follow-up, maintenance therapies or inclusion in therapeutic studies. The dichotomous prognostic value of KATNAL2 should be validated in larger sample sets of EOC.

Citing Articles

Multiple machine learning-based integrations of multi-omics data to identify molecular subtypes and construct a prognostic model for HNSCC.

Luo X, Li C, Qin G Hereditas. 2025; 162(1):17.

PMID: 39910672 PMC: 11800565. DOI: 10.1186/s41065-025-00380-0.

Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma.

Tang J, Yang L, Wu Q, Yang Y, Su Y, Chen Y Funct Integr Genomics. 2024; 24(4):122.

PMID: 38980439 DOI: 10.1007/s10142-024-01398-9.

RUNX transcription factors: biological functions and implications in cancer.

Chen X, Wang L, Yang M, Zhao W, Tu J, Liu B Clin Exp Med. 2024; 24(1):50.

PMID: 38430423 PMC: 10908630. DOI: 10.1007/s10238-023-01281-0.

Revealing Tissue Heterogeneity and Spatial Dark Genes from Spatially Resolved Transcriptomics by Multiview Graph Networks.

Li Y, Lu Y, Kang C, Li P, Chen L Research (Wash D C). 2023; 6:0228.

PMID: 37736108 PMC: 10511271. DOI: 10.34133/research.0228.

RUNX3 Meets the Ubiquitin-Proteasome System in Cancer.

Toska A, Modi N, Chen L Cells. 2023; 12(5).

PMID: 36899853 PMC: 10001085. DOI: 10.3390/cells12050717.

References

Petsalaki E, Zachos G . DNA damage response proteins regulating mitotic cell division: double agents preserving genome stability. FEBS J. 2020; 287(9):1700-1721. DOI: 10.1111/febs.15240. View

Maxwell C, Benitez J, Gomez-Baldo L, Osorio A, Bonifaci N, Fernandez-Ramires R . Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011; 9(11):e1001199. PMC: 3217025. DOI: 10.1371/journal.pbio.1001199. View

Yuecheng Y, Hongmei L, Xiaoyan X . Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 2006; 23(1):65-74. DOI: 10.1007/s10585-006-9020-3. View

Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S . Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2019; 56(9):574-580. DOI: 10.1136/jmedgenet-2018-105930. View

Li N, Nan C, Zhong X, Weng J, Fan H, Sun H . miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1. Cell Physiol Biochem. 2018; 49(4):1329-1341. DOI: 10.1159/000493411. View

Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M . Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31(9):1240-1250. PMC: 7484370. DOI: 10.1016/j.annonc.2020.05.019. View

Jin Z, Liu Y . DNA methylation in human diseases. Genes Dis. 2018; 5(1):1-8. PMC: 6147084. DOI: 10.1016/j.gendis.2018.01.002. View

Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, Gajda M . Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Int J Cancer. 2017; 141(8):1600-1614. DOI: 10.1002/ijc.30860. View

Potapova A, Hoffman A, Godwin A, Al-Saleem T, Cairns P . Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 2008; 68(4):998-1002. DOI: 10.1158/0008-5472.CAN-07-2418. View

10.

Michaelson-Cohen R, Keshet I, Straussman R, Hecht M, Cedar H, Beller U . Genome-wide de novo methylation in epithelial ovarian cancer. Int J Gynecol Cancer. 2011; 21(2):269-79. DOI: 10.1097/IGC.0b013e31820e5cda. View

11.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

12.

Sorensen S, Schnack T, Hogdall C . Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstet Gynecol Scand. 2018; 98(1):34-43. DOI: 10.1111/aogs.13453. View

13.

Natanzon Y, Goode E, Cunningham J . Epigenetics in ovarian cancer. Semin Cancer Biol. 2017; 51:160-169. PMC: 5976557. DOI: 10.1016/j.semcancer.2017.08.003. View

14.

Duffy M, Napieralski R, Martens J, Span P, Spyratos F, Sweep F . Methylated genes as new cancer biomarkers. Eur J Cancer. 2009; 45(3):335-46. DOI: 10.1016/j.ejca.2008.12.008. View

15.

Kobayashi H, Ohno S, Sasaki Y, Matsuura M . Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep. 2013; 30(3):1019-29. DOI: 10.3892/or.2013.2541. View

16.

Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

17.

Lendvai A, Johannes F, Grimm C, Eijsink J, Wardenaar R, Volders H . Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics. 2012; 7(11):1268-78. PMC: 3499328. DOI: 10.4161/epi.22301. View

18.

Gu H, Gu S, Zhang X, Zhang S, Zhang D, Lin J . miR-106b-5p promotes aggressive progression of hepatocellular carcinoma via targeting RUNX3. Cancer Med. 2019; 8(15):6756-6767. PMC: 6825988. DOI: 10.1002/cam4.2511. View

19.

Kuo Y, Howard J . Cutting, Amplifying, and Aligning Microtubules with Severing Enzymes. Trends Cell Biol. 2020; 31(1):50-61. PMC: 7749064. DOI: 10.1016/j.tcb.2020.10.004. View

20.

McLaughlin J, Rosen B, Moody J, Pal T, Fan I, Shaw P . Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst. 2012; 105(2):141-8. PMC: 3611851. DOI: 10.1093/jnci/djs494. View